Odonate Therapeutics trades as part of the healthcare sector and is in the biotechnology industry. The company CEO is Kevin C. Tang. Odonate Therapeutics Inc is a pharmaceutical company which is engaged in the development of therapeutics which improves and extend the lives of patients with cancer. It is developing tesetaxel an chemotherapy agent used in the treatment of cancer.

Previous Intraday Performance:

The ODT shares had a previous change of 0.88% which opened at 19.37 and closed at 19.49. It moved to an intraday high of 19.65 and a low of 19.20.

SeekingAlpha:  Daily Insider Ratings Round Up 3/11/19

Historical Performance:

Over the last five trading days, ODT shares returned 12.27% and in the past 30 trading days it returned 19.94%. Over three months, it changed 27.97%. In one year it has changed -31.83% and within that year its 52-week high was 29.31 and its 52-week low was 11.54. ODT stock is 68.89% above its 52 Week Low.

Our calculations result in a 200 day moving average of 18.61 and a 50 day moving average of 16.39. Right now, ODT stock is trading 4.71% above its 200 day moving average and may be a good opportunity to buy.

SeekingAlpha:  Daily Insider Ratings Round Up 3/11/19


The company has a market cap of $521.4m with 26.8m shares outstanding and a float of 26.1m shares. Trading volume was 61,427 shares and has experienced an average volume of 39,795 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Odonate Therapeutics was -3.63 which ended on 31st of December 2018.

Below was the last reported quarterly earnings per share:
12-31-2018:  -1.17
09-30-2018:  -0.98
06-30-2018:  -0.79
03-31-2018:  -0.69

Base on our calculations, the intrinsic value per share is 59.02, which means it might be undervalued and has a margin of safety of 66.98%

The next earnings report will be: 03-20-2019

The long-term trend of the EPS is a vital number as it helps understand the future potential of Odonate Therapeutics; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is unavialble, but historically the EPS change was -44.44% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 109.50% of institutional ownership.

I calculated the beta to be 0.96

Business Wire:  Prana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System Atrophy

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -57.10%, return on assets is -52.72% and price-to-book is 4.17.

Company Score Card:

Results are out of six:
 3  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 2  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here